Navigation Links
Research identifies trigger that sets of Huntingtons disease

Researchers have discovered the key molecule that gets over activated by the protein of the Huntingtons disease// and sets way for the condition to be expressed.

Huntingtons disease is a genetic disorder that slowly destroys the ability of the person to think or move by himself. Early symptoms of the disease may be depression, mood swings, forgetfulness, and inability to concentrate or remember. In severe condition, the person is unable to take care of himself, and may die of infection, choking or cardiac arrest.

The protein of the Huntingtons disease (HD) activates a regular protein called p53. The p53 can lead to expression of some other genes, that can lead to the full fledged expression of the genes. Researchers from Johns Hopkins University School of Medicine, who had conduced the study, feel that the molecule p53 may also be responsible for Parkinson's disease and amyotrophic lateral sclerosis, also called Lou Gehrigs disease.

The research establishes a specific role for p53 in Huntingtons disease, as a nuclear transcription factor that regulates various mitochondrial genes. The research findings thus link the disturbances of nuclei and mitochondria in the disease condition.

Reference: Neuron, July 2005
'"/>




Page: 1

Related medicine news :

1. Kidney Stones - Interesting New Research implicates bacteria as its cause
2. Researchers urge caution in using ear tube surgery
3. Paracetamol May Cause Live Damage Warns Consumer Education and Research Centre
4. Researchers Scale to assess the Severity of Epilepsy in Kids
5. Research of Ritalin
6. Researchers trick Alzheimers Enzyme
7. Researchers find new HIV hiding place
8. A Compilation of recent Diabetes Research articles
9. Research on causes for falling helps develop preventive strategies
10. New standards for Human Research Safety
11. Research on Celiac Disease in children
Post Your Comments:
Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Dendreon Announces Webcast Presentations at Upcoming Investor Conferences 13867 1Women Urged Not to Drink While Pregnant 56308 1Women Urged Not to Drink While Pregnant 56308 2Women Urged Not to Drink While Pregnant 56308 3Amgen to Present at the Baird Healthcare Conference 56306 1Amgen to Present at the Baird Healthcare Conference 56306 2